Erasca Revamps With Two In-Licensings, $160m Follow-On Offering
The San Diego biotech is also de-emphasizing three ongoing targeted cancer therapy candidates and giving itself the flexibility to focus on RAS- or KRAS-targeting approaches.
The San Diego biotech is also de-emphasizing three ongoing targeted cancer therapy candidates and giving itself the flexibility to focus on RAS- or KRAS-targeting approaches.